Brief: Mereo Biopharma To Present Data Update For The Phase 1B/2 Study (Activate) Of Etigilimab And Nivolumab At 2022 Asco Annual Meeting Mereo Also Updates Capital Allocation And Portfolio Prioritization Plan

Mereo BioPharma

02/06/2022 13:14

June 2 (Reuters) - Mereo Biopharma Group PLC  MAH0y.F :
    * MEREO BIOPHARMA TO PRESENT DATA UPDATE FOR THE PHASE 1B/2
STUDY
(ACTIVATE) OF  ETIGILIMAB AND NIVOLUMAB AT 2022 ASCO ANNUAL
MEETING; MEREO ALSO UPDATES CAPITAL ALLOCATION AND PORTFOLIO
PRIORITIZATION PLAN
    * MEREO BIOPHARMA GROUP PLC- ETIGILIMAB SAFE AND WELL
TOLERATED,
NO NEW SAFETY SIGNALS
    * MEREO BIOPHARMA GROUP- ACTIVATE INCLUDES 2 COMPLETE
RESPONSES, 4
PARTIAL RESPONSES AND 10 PATIENTS WITH STABLE DISEASE AS OF
APRIL 2022 DATA CUT OFF
    * MEREO BIOPHARMA GROUP PLC- PRIORITIZATION INITIATIVES
EXTEND
CASH RUNWAY TO LATE 2024
    * MEREO BIOPHARMA GROUP PLC- INTENDS TO COMPLETE FURTHER
ANALYSIS
OF PHASE 2 DATA DURING 2H 2022

Source text for Eikon:  ID:nGNX6tKgjl 
Further company coverage:  MAH0y.F 

 ((Reuters.Briefs@thomsonreuters.com;))